Roivant Sciences (ROIV) reported fiscal Q4 net income from continuing operations Wednesday of $0.28 per diluted share, swinging from a loss of $0.29 a year earlier.
Analysts polled by FactSet expected losses of $0.29.
Revenue for the quarter ended March 31 was $2.5 million, down from $7.6 million a year earlier.
Analysts surveyed by FactSet expected $3.4 million.
Shares of the company were up 3.2% in recent premarket trading.